# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-clien...
Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $280 to $285.
European Commission Approval Followed By Anticipated EU And UK Launches In Q1 2025; Strategic Partnership With Cencora To Suppo...
Leerink Partners analyst Michael Cherny maintains Cencora (NYSE:COR) with a Outperform and maintains $275 price target.